Fulgent Genetics Provides Update on Testing for Covid-19
End-to-end testing enables Fulgent to more efficiently manage the demand it is seeing for both its RT-PCR and next-generation sequencing tests for Covid-19.
Read MorePosted by | Apr 15, 2020 | Covid 19, Emerging & Zoonotic Diseases, Infectious Diseases |
End-to-end testing enables Fulgent to more efficiently manage the demand it is seeing for both its RT-PCR and next-generation sequencing tests for Covid-19.
Read MorePosted by | Apr 14, 2020 | Cancer, Molecular Diagnostics, Unknown Origin & Other Cancer Types |
Myriad’s myChoice companion diagnostic helps identify women with ovarian cancer who are candidates for maintenance therapy using olaparib with bevacizumab.
Read MorePosted by Steve Halasey | Apr 13, 2020 | Compliance, Computing Systems, Information Technology, Lab Management, Middleware & Software |
AI-driven software can help labs expertly navigate the prior authorization landscape.
Read MorePosted by Steve Halasey | Apr 13, 2020 | Cancer, Molecular Diagnostics, Pancreatic, Specimen Collection & Handling |
Analysis of cell-free DNA in blood samples is revolutionizing cancer treatment and prognosis.
Read MorePosted by | Apr 10, 2020 | Cancer, Leukemia, Molecular Diagnostics |
The latest update is beneficial to researchers investigating myeloid disorders, and is now enabled with BCR-ABL fusion gene and KMT2A-PTD detection.
Read More